Abstract
The compositional and metabolic heterogeneity of operationally defined plasma lipoprotein classes (1-3) has necessitated the introduction of a classification system that utilizes apolipoproteins as specific markers for identifying and distinguishing discrete lipoprotein particles (1,4). In this system, lipoprotein particles are characterized and defined by their apolipoprotein composition (1,4). Studies on the quantification and distribution of apolipoproteins (4,5) have shown that apolipoprotein (Apo)B and ApoA (A-I 4- A-II) form two major groups of plasma lipoproteins. These two major lipoprotein groups may be separated (6) by immunoprecipitation or immunoaffinity chromatography of whole plasma (6). The use of these procedures results in the isolation of ApoA-containing lipoproteins free of ApoB. The fractionation of ApoA-containing lipoproteins into two major discrete lipoprotein particles LP-A-I and LP-A-I:A-II by immunoaffinity chromatography on an immunosorber with polyclonal antibodies to ApoA-II has already been described by Cheung and Albers (7). To identify discrete lipoprotein particles of the ApoB group of lipoproteins, we have developed a procedure based on sequential immunoprecipitation of ApoB-containing lipoproteins with polyclonal antisera to apolipoproteins B, E, C-III and, if necessary, C-II and C-I (6,8). The fractionation of very low density (VLDL, d < 1.006 g/ml) and two subtractions of low density (LDL.., d = 1.006-1.019 g/ml; LDL?, d = 1.019-1.063 g/ml lipoproteins from normolipidemic subjects by sequential immunoprecipitation showed that each of these density classes consists of a mixture of distinct lipoprotein particles including cholesterol ester-rich LP-B and triglyceride- rich LP-B:C-I:C-II:C-III:E (LP-B:C:E) and LP-B:C-I: C-II:C-III (LP-B:C) particles (8). The LP-B:C:E family of particles in some normolipidemic and hypercholesterolemic subjects also contained varying amounts of LP-B:E particles. In addition, small amounts of LP-B:C-I:E, LP-B:C-II, LP-C-III and LP-E particles were detected in some but not all-subjects or density classes. Each of the major ApoB-containing families of particles was shown to represent a polydisperse system of particles heterogeneous with respect to size, hydrated density, and lipid/protein ratio, but homogeneous with respect to the qualitative apolipoprotein composition.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
P. Alaupovic, The role of apolipoproteins in lipid transport processes, La Ricerca Clin. Lab. 12:3 (1982).
C.J. Packard and J. Shepherd, Models and mechanisms in very low density lipoprotein metabolism, Eur. J. Clin. Invest. 15:51 (1985).
K. Lippel, S. Gianturco, A. Fogelman, P. Nestel, S.M. Grundy, W. Fisher, A. Chait, J. Albers, and P.S. Roheim, Lipoprotein heterogeneity workshop, Arterioslcerosis 7:315 (1987).
P. Alaupovic, The concepts, classification systems, and nomenclature of human plasma lipoproteins, in: “CRC Handbook of Electrophoresis. Lipoproteins: basic principles and concepts”, L.A. Lewis and J.J. Opplt, eds., CRC Press, Inc., Boca Raton, Florida, Vol. I (1980).
P. Alaupovic, The physicochemical and immunological heterogeneity of human plasma high-density lipoproteins, in: “Clinical and Metabolic Aspects of High-density Lipoproteins”, N.E. Miller and G.J. Miller, eds., Elsevier Science Publishers B.V., Amsterdam (1984).
P. Alaupovic, E. Koren, W.J. McConathy, M. Tavella, C. Knight-Gibson, and J.D. Fesmire, Immunochemical methods of isolating and characterizing ApoB-containing lipoproteins, in: “Proceedings of the Workshop on Lipoprotein Heterogeneity”, K. Lippel, ed., National Institutes of Health, NIH Publication No. 87-2646, Bethesda, MD (1987).
M. Cheung and J.J. Albers, Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but not A-II,J. Biol. Chem. 259:12201 (1984).
P. Alaupovic, M. Tavella, and J. Fesmire, Separation and identification of ApoB-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias, Adv. Exp. Med. Biol. 210:7 (1987).
C.-S. Wang, P. Alaupovic, R.E. Gregg, and H.B. Brewer, Jr., Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k.. values and apolipoprotein composition of the major lipoprotein density classes, Biochim. Biophys. Acta 920:9 (1987).
P. Alaupovic, C. Knight-Gibson, C.-S. Wang, D. Downs, E. Koren, H.B. Brewer, Jr., and R. Gregg, Possible association of a newly recognized ApoA-II-containing lipoprotein and hypertriglyceridemia in Tangier disease, Arteriosclerosis 7:536a (1987).
Lipid Research Clinics Laboratory Manual 1, DHEW No. (NIH)75-628, National Heart and Lung Institute, Bethesda, MD (1974).
P. O. Attman, P. Alaupovic, and A. Gustafson, Serum apolipoprotein profile of patients with chronic renal failure, Kidney International 32:368 (1987).
J.M. Bard, P. Alaupovic, and D. Shafer, Lipoprotein abnormalities common to all patients with type II diabetes mellitus, Arteriosclerosis 7:536a (1987).
P. Alaupovic, D.M. Lee, and W.J. McConathy, Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins, Biochim. Biophy. Acta 260:689 (1972).
P. Alaupovic, C.-S. Wang, W.J. McConathy, D. Weiser, and D. Downs, Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product, Arch. Biochem. 244:226 (1986).
E. Koren, W.J. McConathy, J. Keeling, R. Schwiedessen, C. Knight-Gibson, G. Wen, and Z. Reiner, The use of “pan” monoclonal antibody for quantification of apolipoprotein A-II, Arteriosclerosis 6:521a (1986).
N. Dashti, P. Alaupovic, C. Knight-Gibson, and E. Koren, Identification and partial characterization of discrete ApoB-containing lipoprotein particles produced by human hepatoma cell line HepG2, Biochemistry 26:4837 (1987).
A. Kuksis, J.J. Myher, L. Marai, and K. Gehler, Determination of plasma lipid profiles by automated gas chromatography and computerized data analyses, J. Chromatogr. Sci. 13:423 (1975).
P. Puchois, A. Kandoussi, P. Fievet, J.L. Fourrier, M. Bertrand, E. Koren and J.C. Fruchart, Apolipoprotein A-I containing lipoproteins in coronary artery disease, Atherosclerosis 68:35 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Alaupovic, P. et al. (1988). Lipoprotein Particles in Hypertriglyceridemic States. In: Malmendier, C.L., Alaupovic, P. (eds) Eicosanoids, Apolipoproteins, Lipoprotein Particles, and Atherosclerosis. Advances in Experimental Medicine and Biology, vol 243. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0733-4_37
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0733-4_37
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8055-2
Online ISBN: 978-1-4613-0733-4
eBook Packages: Springer Book Archive